Literature DB >> 22072818

Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Kelly A Berg1, Matthew P Rowan, Achla Gupta, Teresa A Sanchez, Michelle Silva, Ivone Gomes, Blaine A McGuire, Philip S Portoghese, Kenneth M Hargreaves, Lakshmi A Devi, William P Clarke.   

Abstract

The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [D-Pen(2,5)]-enkephalin (DPDPE), decreased the potency of [D-Ala(2),D-Leu(5)]-enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide (SNC80) to inhibit prostaglandin E(2) (PGE(2))-stimulated adenylyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE(2)-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5'-guanidinonaltrindole (5'-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6'-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE(2)-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072818      PMCID: PMC3263945          DOI: 10.1124/mol.111.072702

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.

Authors:  Rashmi G Bhushan; Shiv K Sharma; Zhihua Xie; David J Daniels; Philip S Portoghese
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

Review 2.  Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

Authors:  Peter Keov; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropharmacology       Date:  2010-07-15       Impact factor: 5.250

Review 3.  The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions.

Authors:  Kjell Fuxe; Daniel Marcellino; Dasiel Oscar Borroto-Escuela; Malgorzata Frankowska; Luca Ferraro; Diego Guidolin; Francisco Ciruela; Luigi F Agnati
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

4.  Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

5.  Regulation of κ-opioid receptor signaling in peripheral sensory neurons in vitro and in vivo.

Authors:  Kelly A Berg; Matthew P Rowan; Teresa A Sanchez; Michelle Silva; Amol M Patwardhan; Stephen B Milam; Kenneth M Hargreaves; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2011-04-12       Impact factor: 4.030

6.  Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.

Authors:  S K Sharma; R M Jones; T G Metzger; D M Ferguson; P S Portoghese
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

7.  II - Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists.

Authors:  S H Ferreira; M Nakamura
Journal:  Prostaglandins       Date:  1979-08

8.  Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord.

Authors:  Philip S Portoghese; Mary M Lunzer
Journal:  Eur J Pharmacol       Date:  2003-04-25       Impact factor: 4.432

9.  N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.

Authors:  Ajay S Yekkirala; Mary M Lunzer; Christopher R McCurdy; Michael D Powers; Alexander E Kalyuzhny; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-08       Impact factor: 11.205

10.  Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.

Authors:  Sandrine Hilairet; Monsif Bouaboula; Dominique Carrière; Gerard Le Fur; Pierre Casellas
Journal:  J Biol Chem       Date:  2003-04-10       Impact factor: 5.157

View more
  34 in total

1.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 2.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

3.  Native serotonin 5-HT2C receptors are expressed as homodimers on the apical surface of choroid plexus epithelial cells.

Authors:  Katharine Herrick-Davis; Ellinor Grinde; Tara Lindsley; Milt Teitler; Filippo Mancia; Ann Cowan; Joseph E Mazurkiewicz
Journal:  Mol Pharmacol       Date:  2015-01-21       Impact factor: 4.436

4.  Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.

Authors:  Laura C Sullivan; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2015-01-30       Impact factor: 4.030

5.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

Review 6.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 7.  G Protein-Coupled Receptor Heteromers.

Authors:  Ivone Gomes; Mohammed Akli Ayoub; Wakako Fujita; Werner C Jaeger; Kevin D G Pfleger; Lakshmi A Devi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-22       Impact factor: 13.820

8.  Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Authors:  Raehannah J Jamshidi; Blaine A Jacobs; Laura C Sullivan; Teresa A Chavera; Rachel M Saylor; Thomas E Prisinzano; William P Clarke; Kelly A Berg
Journal:  J Pharmacol Exp Ther       Date:  2015-08-21       Impact factor: 4.030

9.  Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Authors:  Laura C Sullivan; Teresa S Chavera; Raehannah J Jamshidi; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-22       Impact factor: 4.030

10.  Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay.

Authors:  Ivone Gomes; Salvador Sierra; Lakshmi A Devi
Journal:  Curr Protoc Pharmacol       Date:  2016-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.